Organogenesis Confirmed to Start FDA License Application for ReNu

Dow Jones12-16

By Katherine Hamilton

Organogenesis received confirmation to initiate a license application with the Food and Drug Administration for its knee condition treatment ReNu.

The regenerative tissue company said Monday it plans to initiate a rolling Biologics License Application for ReNu before the end of December.

Shares gained 9% to $5.28 in after-hours trading.

The plans come after a planned Type-B meeting with the FDA, which was completed Monday, Organogenesis said.

Organogenesis has done two large Phase 3 trials of ReNu, plus a separate randomized controlled trial.

ReNu is designed to treat people with symptomatic knee osteoarthritis, a degenerative condition that causes knee pain. It affects 31.1 million Americans and is ranked among the most common causes of disability and poor quality of life, Organogenesis said.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

December 15, 2025 17:11 ET (22:11 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591227756?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-16 06:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591227756","market":"sh","top_or_hot":-1,"title":"Organogenesis Confirmed to Start FDA License Application for ReNu","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Organogenesis received confirmation to initiate a license application with the Food and Drug Administration for its knee condition treatment ReNu. \n</p>\n<p>\n  The regenerative tissue company said Monday it plans to initiate a rolling Biologics License Application for ReNu before the end of December. \n</p>\n<p>\n  Shares gained 9% to $5.28 in after-hours trading. \n</p>\n<p>\n  The plans come after a planned Type-B meeting with the FDA, which was completed Monday, Organogenesis said. \n</p>\n<p>\n  Organogenesis has done two large Phase 3 trials of ReNu, plus a separate randomized controlled trial. \n</p>\n<p>\n  ReNu is designed to treat people with symptomatic knee osteoarthritis, a degenerative condition that causes knee pain. It affects 31.1 million Americans and is ranked among the most common causes of disability and poor quality of life, Organogenesis said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 15, 2025 17:11 ET (22:11 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Organogenesis Confirmed to Start FDA License Application for ReNu</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrganogenesis Confirmed to Start FDA License Application for ReNu\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-16 06:11</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Organogenesis received confirmation to initiate a license application with the Food and Drug Administration for its knee condition treatment ReNu. \n</p>\n<p>\n  The regenerative tissue company said Monday it plans to initiate a rolling Biologics License Application for ReNu before the end of December. \n</p>\n<p>\n  Shares gained 9% to $5.28 in after-hours trading. \n</p>\n<p>\n  The plans come after a planned Type-B meeting with the FDA, which was completed Monday, Organogenesis said. \n</p>\n<p>\n  Organogenesis has done two large Phase 3 trials of ReNu, plus a separate randomized controlled trial. \n</p>\n<p>\n  ReNu is designed to treat people with symptomatic knee osteoarthritis, a degenerative condition that causes knee pain. It affects 31.1 million Americans and is ranked among the most common causes of disability and poor quality of life, Organogenesis said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 15, 2025 17:11 ET (22:11 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ORGO","symbol_name":"Organogenesis Holdings Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2591227756","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591227756","pubTimestamp":1765836660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Organogenesis received confirmation to initiate a license application with the Food and Drug Administration for its knee condition treatment ReNu.The regenerative tissue company said Monday it plans to initiate a rolling Biologics License Application for ReNu before the end of December.Shares gained 9% to $5.28 in after-hours trading.The plans come after a planned Type-B meeting with the FDA, which was completed Monday, Organogenesis said.Organogenesis has done two large Phase 3 trials of ReNu, plus a separate randomized controlled trial.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ORGO":"Organogenesis Holdings Inc","BK4139":"生物科技"},"translate_title":"Organogenesis确认开始ReNu的FDA许可申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ORGO":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Organogenesis received confirmation to initiate a license application with the Food and Drug Administration for its knee condition treatment ReNu. \n\n\n  The regenerative tissue company said Monday it plans to initiate a rolling Biologics License Application for ReNu before the end of December. \n\n\n  Shares gained 9% to $5.28 in after-hours trading. \n\n\n  The plans come after a planned Type-B meeting with the FDA, which was completed Monday, Organogenesis said. \n\n\n  Organogenesis has done two large Phase 3 trials of ReNu, plus a separate randomized controlled trial. \n\n\n  ReNu is designed to treat people with symptomatic knee osteoarthritis, a degenerative condition that causes knee pain. It affects 31.1 million Americans and is ranked among the most common causes of disability and poor quality of life, Organogenesis said. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 15, 2025 17:11 ET (22:11 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591227756","isCrawlerRequest":true}